PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Parent market
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Prophylactic vaccines – Market size and forecast 2019-2024
• Therapeutic vaccines – Market size and forecast 2019-2024
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• R&D of novel vaccines
• Development of nanoparticle vaccines
• Advancement in vaccine delivery system
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bavarian Nordic AS
• CSL Ltd.
• Emergent BioSolutions Inc.
• GlaxoSmithKline Plc
• Inovio Pharmaceuticals Inc.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novavax Inc.
• Pfizer Inc.
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Type – Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Prophylactic vaccines – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Prophylactic vaccines – Year-over-year growth 2020-2024 (%)
Exhibit 22: Therapeutic vaccines – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Therapeutic vaccines – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America – Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bavarian Nordic AS – Vendor overview
Exhibit 49: Bavarian Nordic AS – Business segments
Exhibit 50: Bavarian Nordic AS – Organizational developments
Exhibit 51: Bavarian Nordic AS – Geographic focus
Exhibit 52: Bavarian Nordic AS – Key offerings
Exhibit 53: Bavarian Nordic AS – Key customers
Exhibit 54: CSL Ltd. – Vendor overview
Exhibit 55: CSL Ltd. – Business segments
Exhibit 56: CSL Ltd. – Organizational developments
Exhibit 57: CSL Ltd. – Geographic focus
Exhibit 58: CSL Ltd. – Segment focus
Exhibit 59: CSL Ltd. – Key offerings
Exhibit 60: CSL Ltd. – Key customers
Exhibit 61: Emergent BioSolutions Inc. – Vendor overview
Exhibit 62: Emergent BioSolutions Inc. – Business segments
Exhibit 63: Emergent BioSolutions Inc. – Organizational developments
Exhibit 64: Emergent BioSolutions Inc. – Key offerings
Exhibit 65: Emergent BioSolutions Inc. – Key customers
Exhibit 66: GlaxoSmithKline Plc – Vendor overview
Exhibit 67: GlaxoSmithKline Plc – Business segments
Exhibit 68: GlaxoSmithKline Plc – Organizational developments
Exhibit 69: GlaxoSmithKline Plc – Geographic focus
Exhibit 70: GlaxoSmithKline Plc – Segment focus
Exhibit 71: GlaxoSmithKline Plc – Key offerings
Exhibit 72: GlaxoSmithKline Plc – Key customers
Exhibit 73: Inovio Pharmaceuticals Inc. – Vendor overview
Exhibit 74: Inovio Pharmaceuticals Inc. – Business segments
Exhibit 75: Inovio Pharmaceuticals Inc. – Organizational developments
Exhibit 76: Inovio Pharmaceuticals Inc. – Key offerings
Exhibit 77: Inovio Pharmaceuticals Inc. – Key customers
Exhibit 78: Merck & Co. Inc. – Vendor overview
Exhibit 79: Merck & Co. Inc. – Business segments
Exhibit 80: Merck & Co. Inc. – Organizational developments
Exhibit 81: Merck & Co. Inc. – Geographic focus
Exhibit 82: Merck & Co. Inc. – Segment focus
Exhibit 83: Merck & Co. Inc. – Key offerings
Exhibit 84: Merck & Co. Inc. – Key customers
Exhibit 85: Mitsubishi Tanabe Pharma Corp. – Vendor overview
Exhibit 86: Mitsubishi Tanabe Pharma Corp. – Business segments
Exhibit 87: Mitsubishi Tanabe Pharma Corp. – Organizational developments
Exhibit 88: Mitsubishi Tanabe Pharma Corp. – Geographic focus
Exhibit 89: Mitsubishi Tanabe Pharma Corp. – Key offerings
Exhibit 90: Mitsubishi Tanabe Pharma Corp. – Key customers
Exhibit 91: Novavax Inc. – Vendor overview
Exhibit 92: Novavax Inc. – Business segments
Exhibit 93: Novavax Inc. – Organizational developments
Exhibit 94: Novavax Inc. – Key offerings
Exhibit 95: Novavax Inc. – Key customers
Exhibit 96: Pfizer Inc. – Vendor overview
Exhibit 97: Pfizer Inc. – Business segments
Exhibit 98: Pfizer Inc. – Organizational developments
Exhibit 99: Pfizer Inc. – Geographic focus
Exhibit 100: Pfizer Inc. – Segment focus
Exhibit 101: Pfizer Inc. – Key offerings
Exhibit 102: Pfizer Inc. – Key customers
Exhibit 103: Sanofi – Vendor overview
Exhibit 104: Sanofi – Business segments
Exhibit 105: Sanofi – Organizational developments
Exhibit 106: Sanofi – Geographic focus
Exhibit 107: Sanofi – Segment focus
Exhibit 108: Sanofi – Key offerings
Exhibit 109: Sanofi – Key customers
Exhibit 110: Validation techniques employed for market sizing
Exhibit 111: Definition of market positioning of vendors
【掲載企業】
Bavarian Nordic AS, CSL Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novavax Inc., Pfizer Inc., and Sanofi.
【免責事項】
https://www.marketreport.jp/reports-disclaimer